SHARE

Advaxis, Inc. (NASDAQ:ADXS) has announced that its poster presentation, concerning its phase 2 study of Lm immunotherapy candidate for head and neck cancer, has been selected at the AACR annual meeting as a late-breaker. Only the presentations, which have a high scientific priority, are accepted after the initial deadline, by the AACR. Added to this, the presentation would also need to include data, which was not previously available, before the original deadline.

The lead of this particular phase 2 study is Andrew G. Sikora, who is an Associate Professor at the Baylor College of Medicine. He is also the co-director of the Head and Neck Cancer Program at the institution. The study is focused at using AXAL as a neo-adjuvant treatment, prior to opting for robot-assisted surgery. As per the details of the presentation, the drug targets and also induces a T-cell response in the tumor. It should be noted here that the study was funded by the US FDA and had obtained a grant of $1.1 million. The drug is classified as an orphan drug.

The AACR meeting is due to be held in New Orleans, from April 16 to 20. The theme of this year’s meeting is “Delivering Cures through Cancer Science”. The CEO of Advaxis, Daniel J. O’Connor, stated that the company is still assessing the potential of AXAL in treating HPV-related cancers. He also expressed his delight at being able to present at the AACR conference.

However, that is not the only meeting that the company would be attending, in the near future. Advaxis has also announced that it will present at the “Cowen and Company’s 36th Annual Health Care Conference.” The conference is due to be held on March 9, in Boston. Mr. Daniel would be present on behalf of ADXS. It is expected that he would update about milestones and progress of the company.

Advaxis, Inc. (NASDAQ:ADXS) gained a total of 26.61%, during the March 2 session, after having a trade volume of 2.68 million, to close at $7.47.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY